Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03742102 · ClinicalTrials.gov registry record · Phase 1
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
A Phase 1 study of Triple Negative Breast Neoplasms, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 243
- Enrollment target
- 20
- Study locations
NCT03742102: Active Phase 1 study of Triple Negative Breast Neoplasms, sponsored by AstraZeneca.
NCT03742102 is a Phase 1 study of Triple Negative Breast Neoplasms that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 243 participants, below the 639-participant average among 10 other Triple Negative Breast Neoplasms trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03742102, a Phase 1 study of Triple Negative Breast Neoplasms, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 243 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
Primary Outcome
The occurrence of a severe adverse event (meeting pre-specified criteria) that is at least possibly related to durvalumab and/or the novel oncology therapy in 6 DLT-evaluable patients
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG Trastuzumab deruxtecan
- DRUG Capivasertib
- DRUG Durvalumab
- DRUG Oleclumab
Study Locations (20)
Other
- Research Site - Gdansk
- Research Site - Krakow
- Research Site - Lublin
- Research Site - Opole
- Research Site - Rzeszów
- Research Site - Warsaw
- Research Site - Warsaw
- Research Site - Seoul
Massachusetts
- Research Site - Boston
- Research Site - Boston
Quebec
- Research Site - Greenfield Park
- Research Site - Montreal
Arizona
- Research Site - Tucson
Maryland
- Research Site - Columbia
Michigan
- Research Site - Grand Rapids
Missouri
- Research Site - St Louis
Texas
- Research Site - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2018-12-21 |
| Est. Completion | 2027-02-26 |
| Phase | Phase 1 |
What the registry record for NCT03742102 still lists
NCT03742102 is an interventional study that assigns participants to a tested intervention. The registered 243 participants enrollment target is mid-sized for trials with a published cap, below the 639-participant average among 10 other Triple Negative Breast Neoplasms trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Triple Negative Breast Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Paclitaxel is the first listed.
NCT03742102 names 20 study sites across 11 states, led by Other, Massachusetts, Quebec.
Frequently Asked Questions
What is clinical trial NCT03742102 about?
NCT03742102 is a clinical study titled "A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer". This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
What is the current status of trial NCT03742102?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 243 participants. The study started on 2018-12-21. Estimated completion is 2027-02-26.
What conditions does trial NCT03742102 study?
This clinical trial studies the following conditions: Triple Negative Breast Neoplasms.
What interventions are being tested in trial NCT03742102?
The interventions under investigation include: Paclitaxel (DRUG), Trastuzumab deruxtecan (DRUG), Capivasertib (DRUG), Durvalumab (DRUG), Oleclumab (DRUG).
Who is sponsoring clinical trial NCT03742102?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03742102 being conducted?
This trial has 20 study locations across Arizona, Maryland, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03742102's enrollment target sits among peer trials
243 7th of 10 higher than 4 of 10 other Triple Negative Breast Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Triple Negative Breast Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
RECRUITING · Phase 1
-
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
RECRUITING · Phase 1
-
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06253871 · 243 participants · Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
- NCT06289491 · 243 participants · NA
A Trial of Hydrus Microstent Versus Goniotomy
- NCT06536296 · 243 participants · NA
The Impact of Music Medicine on Preterm Brain Development and Behavior
- NCT06907615 · 243 participants · Phase 2
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI